These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17767037)

  • 21. Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics.
    Ishikawa T; Nakagawa H
    J Exp Ther Oncol; 2009; 8(1):5-24. PubMed ID: 19827267
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oligomerization domain of the multidrug resistance-associated transporter ABCG2 and its dominant inhibitory activity.
    Xu J; Peng H; Chen Q; Liu Y; Dong Z; Zhang JT
    Cancer Res; 2007 May; 67(9):4373-81. PubMed ID: 17483351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2.
    Mizuarai S; Aozasa N; Kotani H
    Int J Cancer; 2004 Mar; 109(2):238-46. PubMed ID: 14750175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of the breast cancer resistance protein (ABCG2) in drug transport.
    Mao Q; Unadkat JD
    AAPS J; 2005 May; 7(1):E118-33. PubMed ID: 16146333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies.
    Westover D; Li F
    J Exp Clin Cancer Res; 2015 Dec; 34():159. PubMed ID: 26714461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhancing chemosensitivity in ABCB1- and ABCG2-overexpressing cells and cancer stem-like cells by an Aurora kinase inhibitor CCT129202.
    Cheng C; Liu ZG; Zhang H; Xie JD; Chen XG; Zhao XQ; Wang F; Liang YJ; Chen LK; Singh S; Chen JJ; Talele TT; Chen ZS; Zhong FT; Fu LW
    Mol Pharm; 2012 Jul; 9(7):1971-82. PubMed ID: 22632055
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
    Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
    Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
    Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
    Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mouse ATP-Binding Cassette (ABC) Transporters Conferring Multi-Drug Resistance.
    Li S; Zhang W; Yin X; Xing S; Xie HQ; Cao Z; Zhao B
    Anticancer Agents Med Chem; 2015; 15(4):423-32. PubMed ID: 25929575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance.
    Bruhn O; Cascorbi I
    Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1337-54. PubMed ID: 25162314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human multidrug transporter ABCG2, a target for sensitizing drug resistance in cancer chemotherapy.
    Xu J; Peng H; Zhang JT
    Curr Med Chem; 2007; 14(6):689-701. PubMed ID: 17346156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LRIG1, human EGFR inhibitor, reverses multidrug resistance through modulation of ABCB1 and ABCG2.
    Liu B; Guo Z; Dong H; Daofeng T; Cai Q; Ji B; Zhang S; Wu L; Wang J; Wang L; Zhu X; Liu Y; Chen Q
    Brain Res; 2015 Jun; 1611():93-100. PubMed ID: 25801120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
    Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
    Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationships between multidrug resistance (MDR) and stem cell markers in human chronic myeloid leukemia cell lines.
    Marques DS; Sandrini JZ; Boyle RT; Marins LF; Trindade GS
    Leuk Res; 2010 Jun; 34(6):757-62. PubMed ID: 19969351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
    Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Towards understanding the mechanism of action of the multidrug resistance-linked half-ABC transporter ABCG2: a molecular modeling study.
    Li YF; Polgar O; Okada M; Esser L; Bates SE; Xia D
    J Mol Graph Model; 2007 Mar; 25(6):837-51. PubMed ID: 17027309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenomic importance of ABCG2.
    Cusatis G; Sparreboom A
    Pharmacogenomics; 2008 Aug; 9(8):1005-9. PubMed ID: 18681776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of breast cancer resistance protein on cancer treatment outcomes.
    Ross DD; Nakanishi T
    Methods Mol Biol; 2010; 596():251-90. PubMed ID: 19949928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional characterization of the ABCG2 5' non-coding exon variants: Stem cell specificity, translation efficiency and the influence of drug selection.
    Sándor S; Jordanidisz T; Schamberger A; Várady G; Erdei Z; Apáti Á; Sarkadi B; Orbán TI
    Biochim Biophys Acta; 2016 Jul; 1859(7):943-51. PubMed ID: 27191194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ABCG2: the key to chemoresistance in cancer stem cells?
    An Y; Ongkeko WM
    Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1529-42. PubMed ID: 19708828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.